125 related articles for article (PubMed ID: 33582217)
1. Disulfiram and 6-Thioguanine synergistically inhibit the enzymatic activities of USP2 and USP21.
Lin HC; Kuan Y; Chu HF; Cheng SC; Pan HC; Chen WY; Sun CY; Lin TH
Int J Biol Macromol; 2021 Apr; 176():490-497. PubMed ID: 33582217
[TBL] [Abstract][Full Text] [Related]
2. 6-Thioguanine is a noncompetitive and slow binding inhibitor of human deubiquitinating protease USP2.
Chuang SJ; Cheng SC; Tang HC; Sun CY; Chou CY
Sci Rep; 2018 Feb; 8(1):3102. PubMed ID: 29449607
[TBL] [Abstract][Full Text] [Related]
3. Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21.
Ye Y; Akutsu M; Reyes-Turcu F; Enchev RI; Wilkinson KD; Komander D
EMBO Rep; 2011 Apr; 12(4):350-7. PubMed ID: 21399617
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders.
Kitamura H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834633
[TBL] [Abstract][Full Text] [Related]
5. Saturation scanning of ubiquitin variants reveals a common hot spot for binding to USP2 and USP21.
Leung I; Dekel A; Shifman JM; Sidhu SS
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8705-10. PubMed ID: 27436899
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase holoenzyme inhibitor COH29 interacts with deubiquitinase ubiquitin-specific protease 2 and downregulates its substrate protein cyclin D1.
Zhu M; Wang H; Ding Y; Yang Y; Xu Z; Shi L; Zhang N
FASEB J; 2022 May; 36(5):e22329. PubMed ID: 35476303
[TBL] [Abstract][Full Text] [Related]
7. Yeast Two-Hybrid Analysis for Ubiquitin Variant Inhibitors of Human Deubiquitinases.
Pascoe N; Seetharaman A; Teyra J; Manczyk N; Satori MA; Tjandra D; Makhnevych T; Schwerdtfeger C; Brasher BB; Moffat J; Costanzo M; Boone C; Sicheri F; Sidhu SS
J Mol Biol; 2019 Mar; 431(6):1160-1171. PubMed ID: 30763569
[TBL] [Abstract][Full Text] [Related]
8. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
9. Validation of catalytic site residues of Ubiquitin Specific Protease 2 (USP2) by molecular dynamic simulation and novel kinetics assay for rational drug design.
Ullah S; Junaid M; Liu Y; Chen S; Zhao Y; Wadood A
Mol Divers; 2023 Jun; 27(3):1323-1332. PubMed ID: 35932436
[TBL] [Abstract][Full Text] [Related]
10. Transient kinetic analysis of USP2-catalyzed deubiquitination reveals a conformational rearrangement in the K48-linked diubiquitin substrate.
Bozza WP; Liang Q; Gong P; Zhuang Z
Biochemistry; 2012 Dec; 51(50):10075-86. PubMed ID: 23211065
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
[TBL] [Abstract][Full Text] [Related]
12. The molecular determinants for distinguishing between ubiquitin and NEDD8 by USP2.
Shin YC; Chen JH; Chang SC
Sci Rep; 2017 May; 7(1):2304. PubMed ID: 28536428
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.
Göricke F; Vu V; Smith L; Scheib U; Böhm R; Akkilic N; Wohlfahrt G; Weiske J; Bömer U; Brzezinka K; Lindner N; Lienau P; Gradl S; Beck H; Brown PJ; Santhakumar V; Vedadi M; Barsyte-Lovejoy D; Arrowsmith CH; Schmees N; Petersen K
J Med Chem; 2023 Mar; 66(5):3431-3447. PubMed ID: 36802665
[TBL] [Abstract][Full Text] [Related]
14. Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily.
Wrigley JD; Gavory G; Simpson I; Preston M; Plant H; Bradley J; Goeppert AU; Rozycka E; Davies G; Walsh J; Valentine A; McClelland K; Odrzywol KE; Renshaw J; Boros J; Tart J; Leach L; Nowak T; Ward RA; Harrison T; Andrews DM
ACS Chem Biol; 2017 Dec; 12(12):3113-3125. PubMed ID: 29131570
[TBL] [Abstract][Full Text] [Related]
15. The USP21/YY1/SNHG16 axis contributes to tumor proliferation, migration, and invasion of non-small-cell lung cancer.
Xu P; Xiao H; Yang Q; Hu R; Jiang L; Bi R; Jiang X; Wang L; Mei J; Ding F; Huang J
Exp Mol Med; 2020 Jan; 52(1):41-55. PubMed ID: 31956270
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies.
Kona FR; Buac D; M Burger A
Curr Cancer Drug Targets; 2011 Mar; 11(3):338-46. PubMed ID: 21247383
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.
Viola-Rhenals M; Patel KR; Jaimes-Santamaria L; Wu G; Liu J; Dou QP
Curr Med Chem; 2018 Feb; 25(4):506-524. PubMed ID: 29065820
[TBL] [Abstract][Full Text] [Related]
18. Disulfiram's Anticancer Activity: Evidence and Mechanisms.
Jiao Y; Hannafon BN; Ding WQ
Anticancer Agents Med Chem; 2016; 16(11):1378-1384. PubMed ID: 27141876
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival.
Haimerl F; Erhardt A; Sass G; Tiegs G
J Biol Chem; 2009 Jan; 284(1):495-504. PubMed ID: 19001362
[TBL] [Abstract][Full Text] [Related]
20. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies.
Kita Y; Hamada A; Saito R; Teramoto Y; Tanaka R; Takano K; Nakayama K; Murakami K; Matsumoto K; Akamatsu S; Yamasaki T; Inoue T; Tabata Y; Okuno Y; Ogawa O; Kobayashi T
Br J Cancer; 2019 Dec; 121(12):1027-1038. PubMed ID: 31673101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
